Physician profile
Mini Bhaskar
NPI 1366453847
$3,179.37
in general payments reported to CMS, 2019-2025
19 companies · $43.74 in 2025
The $43.74 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,051 · 2020: $355 · 2021: $45.74 · 2022: $211 · 2023: $428 · 2024: $45.18 · 2025: $43.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $502.56 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $613.46 | 2019-2023 | Enbrel, Tavneos, Evenity |
| Abbvie INC. | $433.36 | 2019-2025 | Rinvoq, Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $328.86 | 2019-2024 | |
| Ucb, INC. | $240.49 | 2019-2024 | Cimzia |
| E.R. Squibb & Sons, L.L.C. | $234.61 | 2019-2020 | |
| Genentech USA, INC. | $195.00 | 2019 | |
| Pfizer INC. | $192.06 | 2019-2023 | |
| Lilly USA, LLC | $149.78 | 2019-2023 | Trulicity, Mounjaro, Taltz |
| Celgene Corporation | $144.76 | 2019 | |
| Mallinckrodt Enterprises LLC | $127.35 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $125.01 | 2022-2023 | Saphnelo |
| Radius Health, INC. | $120.55 | 2019-2025 | Tymlos |
| Glaxosmithkline, LLC. | $93.53 | 2019 | |
| Horizon Therapeutics Plc | $43.59 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $40.58 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $32.40 | 2019 | |
| Janssen Biotech, INC. | $32.34 | 2019 | |
| Hikma Pharmaceuticals USA | $16.13 | 2019 | |
| Novo Nordisk INC | $15.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mini Bhaskar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.